1. 69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7. (January 2016) Authors: O'Byrne, K.J.; Park, K.; Tan, E.; Zhang, L.; Hirsh, V.; Boyer, M.; Yang, J.C.; Mok, T.; Kim, M.; Massey, D.; Zazulina, V.; Paz-Ares, L. Journal: Lung cancer Issue: Volume 91(2016)Supplement 1 Page Start: S25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Accuracy of automated three‐dimensional ultrasound imaging technique for fetal head biometry. (3rd May 2021) Authors: Pluym, I. D.; Afshar, Y.; Holliman, K.; Kwan, L.; Bolagani, A.; Mok, T.; Silver, B.; Ramirez, E.; Han, C. S.; Platt, L. D. Journal: Ultrasound in obstetrics & gynecology Issue: Volume 57:Number 5(2021) Page Start: 798 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7). (February 2017) Authors: Hirsh, V.; Park, K.; Tan, E.H.; Zhang, L.; O'Byrne, K.; Boyer, M.; Yang, J.C.H.; Mok, T.; Lee, K.H.; Lu, S.; Shi, Y.; Kim, S.W.; Laskin, J.; Kim, D.W.; Laurie, S.A.; Kölbeck, K.; Fan, J.; Dodd, N.; Märten, A.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S184 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Deoxycytidine kinase expression in AML blasts and its relationship to leukemia‐free and overall survival: PS101. Issue 5 (September 2017) Authors: Ng, L.; Chan, C.; Au, T.; Cheng, C. K.; Mo, K. F.; Li, W.; Lei, K.; Mok, T.; Ng, M.; Raghupathy, R. Journal: Porto biomedical journal Issue: Volume 2:Issue 5(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials. (February 2017) Authors: Schuler, M.; Paz-Ares, L.; Sequist, L.V.; Tan, E.H.; Mok, T.; Hirsh, V.; O'Byrne, K.; Zhang, L.; Yamamoto, N.; Boyer, M.; Shah, R.; Bennouna, J.; Dickgreber, N.J.; De Grève, J.; Love, J.; Märten, A.; Fan, J.; Ehrnrooth, E.; Park, K.; Yang, J.C.H. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗